Study #2022-0130
A Phase 1b Study of gemcitabine and nab-paclitaxel in combination with IM156 in patients with advanced pancreatic cancer.
MD Anderson Study Status
Enrolling
Treatment Agent
Gemcitabine, Nab paclitaxel, IM156
Description
To learn if adding a new medication, IM156, to treatment with gemcitabine and nab-paclitaxel is safe and tolerable. The ability of this combination to improve the success of this treatment for these patients will also be studied.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Pancreas Cancer
Study phase:
Phase I
Physician name:
Shubham Pant
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-855-499-2252
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.